A Green Sign – Lifestyle
Author:
MapLight Therapeutics, Inc.
MapLight Therapeutics to Participate in Upcoming Investor Conferences
May 8, 2026
MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results
May 1, 2026
BANKFIRST CAPITAL CORPORATION Reports First Quarter 2026 Earnings of $8.39 Million
April 29, 2026
MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 26, 2026
MapLight Therapeutics to Participate in Upcoming Investor Conferences
March 5, 2026